Vaxcyte, Inc. Share Price

Vaxcyte, Inc. Share Price

NASDAQ: PCVX | Mid Cap
$59.41
-$2.05 (-3.34%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Vaxcyte, Inc. Stock Performance

Open
$62.15
Prev. Close
$61.47
Circuit Range
N/A
Day Range
$59.08 - $62.49
Year Range
$42.40 - $90.08
Volume
41,635
Average Traded
$59.91

Vaxcyte, Inc. Share Price Today

As of 18 November 2026, Vaxcyte, Inc.'s share price is $59.41. The stock opened at $62.15, compared to its previous close of $61.47. During today's trading session, Vaxcyte, Inc.'s share price traded between $59.08 and $62.49, with an average price of $60.78. Over the past 52 weeks, the stock has recorded a high of $90.08 and a low of $42.40. In terms of performance, Vaxcyte, Inc.'s share price has risen by 15.54% over the last six months and is up 20.07% on a year-on-year basis.

Vaxcyte, Inc. Share Price Chart

Line chart of the Vaxcyte, Inc. price trend over the selected period. The price fell overall, ranging from 59.08 to 62.49, ending at 59.41.
$59.08$62.49
L
Show Current Price
H

Vaxcyte, Inc. Stock Fundamentals & Key Indicators

Market Cap
$8.09B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-7.26
Revenue (TTM)
$0.00
Return On Equity (TTM)
-46.14%
Profit Margin
N/A
Debt to Equity
0.04
Quarterly Earnings Growth YoY
-20.51%

Vaxcyte, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$246.51-$320.62-$284.30-$297.06
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-30.06%11.33%-4.49%

Vaxcyte, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$223.49-$402.27-$463.93-$766.63
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-79.99%-15.33%-65.25%

About Vaxcyte, Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Vaxcyte, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$62.47
$59.44
-4.07%
Oct 2026
$56.89
$61.96
+8.70%
Sep 2026
$60.85
$57.00
-6.73%
Aug 2026
$54.01
$61.12
+13.03%
Jul 2026
$58.02
$54.07
-6.94%
Jun 2026
$50.45
$58.10
+12.98%
May 2026
$56.91
$51.42
-10.22%
Apr 2026
$58.69
$57.28
-1.34%
Mar 2026
$60.14
$58.06
-5.93%
Feb 2026
$53.59
$61.72
+15.11%
Jan 2026
$46.31
$53.62
+16.31%
Dec 2025
$44.98
$46.10
-6.84%

PCVX Share Price FAQs